Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) hit a new 52-week high during trading on Wednesday . The company traded as high as $87.08 and last traded at $86.41, with a volume of 68,087 shares traded. The stock had previously closed at $86.43.

IART has been the topic of a number of research reports. Lake Street Capital boosted their price objective on shares of Integra LifeSciences Holdings Corp. from $57.00 to $75.00 and gave the stock a “hold” rating in a research report on Thursday, April 28th. Jefferies Group reaffirmed a “buy” rating on shares of Integra LifeSciences Holdings Corp. in a research report on Thursday, April 28th. Barclays PLC upped their price target on shares of Integra LifeSciences Holdings Corp. from $77.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Friday, July 29th. Zacks Investment Research lowered shares of Integra LifeSciences Holdings Corp. from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $85.00 price target on shares of Integra LifeSciences Holdings Corp. in a research report on Friday, June 24th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Integra LifeSciences Holdings Corp. presently has a consensus rating of “Buy” and an average price target of $82.88.

The company has a market cap of $3.21 billion and a P/E ratio of 354.59. The firm’s 50-day moving average is $82.33 and its 200 day moving average is $72.00.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.76 by $0.03. The company had revenue of $249.30 million for the quarter, compared to analyst estimates of $243.17 million. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period last year, the business earned $0.79 EPS. On average, equities research analysts predict that Integra LifeSciences Holdings Corp. will post $3.48 EPS for the current fiscal year.

In related news, Director Raymond G. Murphy sold 2,610 shares of Integra LifeSciences Holdings Corp. stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $84.83, for a total value of $221,406.30. Following the completion of the sale, the director now owns 33,057 shares of the company’s stock, valued at approximately $2,804,225.31. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Richard D. Gorelick sold 4,000 shares of Integra LifeSciences Holdings Corp. stock in a transaction on Monday, August 1st. The shares were sold at an average price of $84.60, for a total transaction of $338,400.00. Following the completion of the sale, the vice president now directly owns 9,702 shares of the company’s stock, valued at approximately $820,789.20. The disclosure for this sale can be found here.

Other hedge funds have bought and sold shares of the company. Principal Financial Group Inc. increased its stake in Integra LifeSciences Holdings Corp. by 7.0% in the fourth quarter. Principal Financial Group Inc. now owns 196,763 shares of the company’s stock valued at $13,337,000 after buying an additional 12,904 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in Integra LifeSciences Holdings Corp. by 41.7% in the fourth quarter. Westfield Capital Management Co. LP now owns 432,445 shares of the company’s stock valued at $29,311,000 after buying an additional 127,170 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Integra LifeSciences Holdings Corp. by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 928,232 shares of the company’s stock valued at $62,916,000 after buying an additional 11,339 shares during the last quarter.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.